
Annual report 2025
added 02-25-2026
Schrödinger Financial Ratios 2011-2026 | SDGR
Annual Financial Ratios Schrödinger
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-8.4 | -8.4 | 55.6 | -10.3 | -19.9 | -221.6 | - | - | - | - | - | - | - | - | - |
P/S |
3.4 | 7.5 | 10.5 | 8.5 | 14.5 | 50.2 | - | - | - | - | - | - | - | - | - |
EPS |
-1.4 | -2.6 | 0.6 | -2.1 | -1.4 | -0.4 | -4.1 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
999 M | 1.82 B | 2.36 B | 1.69 B | 2.08 B | 5.34 B | 222 M | 115 M | 103 M | - | - | - | - | - | - |
EBITDA per Share |
-2.19 | -2.8 | -2.39 | -2 | -1.54 | -0.95 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-18.9 | -101.1 | - | - | - | - | - | - | - | - | - | ||||
PEG |
- | -402.9 | - | - | - | - | - | - | - | - | - | ||||
P/B |
2.4 | 3.7 | 4.1 | 3.4 | 3.6 | 8.7 | - | - | - | - | - | - | - | - | - |
P/CF |
62.4 | -9.9 | -16.6 | -12.9 | -28.3 | 323.6 | - | - | - | - | - | - | - | - | - |
ROE % |
-28.37 | -44.40 | 7.42 | -33.31 | -18.02 | -3.92 | - | - | - | - | - | - | - | - | - |
ROA % |
-14.22 | -22.73 | 5.07 | -21.67 | -13.27 | -3.28 | - | - | - | - | - | - | - | - | - |
ROCE % |
-45.84 | -49.66 | -32.35 | -32.78 | -20.00 | -9.76 | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.0 | 2.0 | 3.2 | 2.9 | 3.8 | 6.1 | - | - | - | - | - | - | - | - | - |
DSO |
227.3 | 265.3 | 102.7 | 88.4 | 83.6 | 53.1 | - | - | - | - | - | - | - | - | - |
DPO |
35.6 | 66.5 | 63.1 | 40.1 | 41.6 | 34.3 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
227.3 | 265.3 | 102.7 | 88.5 | 83.6 | 53.0 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
191.7 | 198.8 | 39.6 | 48.4 | 42.0 | 18.7 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Schrödinger
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.45 | -0.59 | -0.82 | -0.52 | -0.74 | -0.76 | -0.86 | 0.06 | 1.81 | - | -0.56 | -0.67 | -0.48 | - | -0.49 | -0.49 | - | - | 0.06 | -0.05 | -0.34 | - | -0.26 | -0.01 | -0.98 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | -0.67 | - | - | -0.91 | - | - | -0.4 | - | -0.6 | -0.61 | -0.39 | - | -0.46 | -0.43 | -0.33 | - | -0.19 | -0.24 | -0.27 | - | -0.19 | -0.27 | -0.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-47.30 | -48.49 | -46.55 | -41.55 | -32.36 | 0.92 | 2.97 | 5.37 | -5.00 | -24.77 | -30.80 | -28.24 | -24.34 | -11.89 | -11.28 | -4.62 | 0.61 | -2.14 | 10.19 | 21.90 | 22.97 | 19.07 | 19.07 | 6.74 | 6.21 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-25.04 | -27.87 | -29.02 | -28.78 | -22.57 | 0.68 | 2.07 | 3.86 | -1.43 | -15.59 | -20.18 | -13.97 | -18.84 | -9.54 | -9.02 | -3.91 | 0.51 | -1.79 | -9.20 | -17.12 | -17.00 | -11.47 | -11.47 | -4.05 | -3.73 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-58.58 | -55.40 | -53.10 | -49.45 | -44.22 | -38.27 | -35.11 | -35.11 | -33.92 | -24.18 | -30.16 | -26.17 | -22.37 | -14.77 | -17.25 | -13.74 | -11.47 | -7.10 | 4.99 | 19.56 | 37.25 | 33.06 | 33.06 | 20.97 | 6.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.0 | 2.0 | 2.0 | 3.0 | 3.2 | 3.3 | 3.4 | 3.6 | 3.4 | 2.9 | 3.3 | - | 3.8 | 3.8 | 4.2 | 6.4 | 6.6 | 6.1 | 6.1 | 6.1 | 6.1 | 2.7 | 2.7 | 2.7 | 2.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
33.1 | 25.4 | 25.8 | 32.5 | 30.5 | 49.5 | 31.7 | 73.0 | 72.3 | - | 29.1 | 34.8 | 57.2 | - | 50.0 | 50.0 | 60.6 | - | 111.2 | 124.2 | 87.3 | - | 85.4 | 89.7 | 41.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
31.3 | 33.0 | 37.0 | 50.2 | 51.6 | 52.3 | 54.8 | 52.1 | 51.3 | - | 25.2 | 20.9 | 39.4 | - | 34.5 | 33.8 | 44.6 | - | 72.8 | 80.6 | 51.6 | - | 34.8 | 35.1 | 20.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
33.1 | 25.4 | 25.8 | 32.5 | 30.5 | 49.5 | 31.7 | 73.0 | 72.3 | - | 29.1 | 34.8 | 57.2 | - | 50.0 | 50.0 | 60.6 | - | 111.2 | 124.2 | 87.3 | - | 85.4 | 89.7 | 41.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
1.9 | -7.6 | -11.3 | -17.7 | -21.1 | -2.8 | -23.2 | 20.9 | 21.0 | - | 3.9 | 13.9 | 17.9 | - | 15.4 | 16.2 | 16.0 | - | 38.3 | 43.6 | 35.8 | - | 50.6 | 54.5 | 20.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Schrödinger, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
HealthStream
HSTM
|
$ 22.03 | 1.52 % | $ 669 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
American Well Corporation
AMWL
|
$ 5.56 | 7.96 % | $ 89.2 M | ||
|
Evolent Health
EVH
|
$ 3.55 | 1.28 % | $ 333 M | ||
|
HealthEquity
HQY
|
$ 81.45 | 1.27 % | $ 6.97 B | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Omnicell
OMCL
|
$ 41.51 | 1.73 % | $ 1.91 B | ||
|
GoodRx Holdings
GDRX
|
$ 2.19 | 5.8 % | $ 845 M | ||
|
Health Catalyst
HCAT
|
$ 1.94 | 12.79 % | $ 117 M | ||
|
Progyny
PGNY
|
$ 17.95 | 2.43 % | $ 1.54 B | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
So-Young International
SY
|
$ 2.89 | 3.96 % | $ 229 M | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
OptimizeRx Corporation
OPRX
|
$ 7.94 | 8.47 % | $ 136 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Phreesia
PHR
|
$ 12.67 | 2.34 % | $ 691 M | ||
|
Zhongchao
ZCMD
|
$ 1.69 | -1.98 % | $ 8.8 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
Teladoc Health
TDOC
|
$ 5.2 | 1.76 % | $ 916 M | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
10x Genomics
TXG
|
$ 22.46 | -0.73 % | $ 2.63 B | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Veeva Systems
VEEV
|
$ 188.53 | 1.38 % | $ 30.3 B | ||
|
SCWorx Corp.
WORX
|
$ 0.14 | -19.22 % | $ 204 K |